Myocardial Infarction News and Research

RSS

Bone marrow-derived mononuclear cell therapy benefits patients after severe heart attack

The first randomized, placebo-controlled U.S. clinical trial to assess the use of bone marrow-derived mononuclear cells (BMC) in patients after a ST-elevation myocardial infarction (STEMI; severe heart attack) demonstrated a strong safety profile for this cell therapy, based on phase 1 results published in the September issue of the American Heart Journal.

15 Sep 2010

World Congress on Arthrosis to take place in Belgium from September 23 to 26, 2010

Over a 1000 experts from the world will participate in the Osteoarthritis Research Society International (OARSI) congress, under the Presidency of the Belgian Professor Yves Henrotin (University of Liège).

14 Sep 2010

Emergency physicians to present research studies at Research Forum 2010

The risks associated with boarding admitted patients in the emergency department – including patient mortality – as well as proposed solutions will be key themes of Scientific Assembly, the annual meeting of the American College of Emergency Physicians. In addition, emergency physicians will present more than 450 research studies during 2010 Research Forum, the premier, annual scientific research event focused on the latest advances in the practice of emergency medicine.

14 Sep 2010

Amorcyte receives patent for chemotactic hematopoietic stem cell product

Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.

13 Sep 2010

NewCardio publishes Cardio3KG clinical study for acute cardiac diagnosis

NewCardio a cardiac diagnostic technology provider, announced today that a clinical study of the Cardio3KG in acute cardiac diagnosis has been published in the August 2010 issue of the peer-reviewed journal, Heart Rhythm, the official journal of the Heart Rhythm Society.

9 Sep 2010

Researchers to study protein fragments released into bloodstream after heart attack

A blood test to diagnose which heart attack survivors will suffer heart failure is the goal of a new five-year, $11.6 million contract to the UT Health Science Center San Antonio from the National Heart, Lung, and Blood Institute (NHLBI).

4 Sep 2010

Data from ESC confirms reduction in adverse events with CYPHER Stent

Additional Analysis of 18 Month Data of the SORT OUT III Trial Provides Detail on Safety and Efficacy Outcomes in Patients With Diabetes, Acute Coronary Syndrome, or Treatment of Multiple Lesions

3 Sep 2010

Iroko Cardio International Sàrl announces data on HDB dosing of tirofiban, abciximab in interventional cardiology

Iroko Cardio International Sàrl announces long-term, three-year, mortality data from the Phase III, open label, multi-national study comparing high-dose bolus (HDB) dosing of AGGRASTAT(tirofiban) (25mcg/kg bolus followed by a 0.15mcg/kg/min infusion for 18-24 hours) vs. ReoPro (abciximab) in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), presented at the 2010 European Society of Cardiology Meeting in Stockholm, Sweden.

3 Sep 2010

InfraReDx receives 510(k) clearance to market LipiScan IVUS Coronary Imaging System

InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that it has received 510(k) clearance from the United States Food and Drug Administration to market the LipiScan IVUS Coronary Imaging System. LipiScan IVUS is the first cardiac catheter to combine intravascular ultrasound and near-infrared spectroscopy to help cardiologists identify and characterize the plaques that complicate stenting and are associated with acute coronary events.

2 Sep 2010

Lack of preparation for winter sports, high altitudes and low temperatures trigger acute myocardial infarction

A study carried out by cardiologists from the Medical University of Innsbruck has investigated the risk of myocardial infarction (heart attack) amongst winter sports tourists to the Tyrolean Alps. The research shows that inadequate preparation for the intense physical exertion required, combined with the effects of altitude and low temperature, leads to an increase in heart attack incidents, particularly during the first two days of vacation.

2 Sep 2010

ESC releases new Clinical Practice Guidelines covering Myocardial Revascularisation

The European Society of Cardiology (ESC) today announces the release of new Clinical Practice Guidelines covering Myocardial Revascularisation. These guidelines were developed following pioneering and extensive co-operation between the ESC and the European Association of Cardio-Thoracic Surgeons (EACTS).

2 Sep 2010

High levels of OPG hormone associated with adverse outcome after myocardial infarction

Patients suffering with heart failure are more likely to die if they have high levels of a bone hormone called osteoprotegerin (OPG).

2 Sep 2010

Incidence of acute myocardial infarction increases among young Italian women: Study

The incidence of acute myocardial infarction in Italy sharply increased, particularly among young women, between the years 2001 and 2005, according to a comprehensive study funded by the Human Health Foundation, a nonprofit Italian charity for biomedical research and health education in Spoleto, Italy. The results were published in Aging Clinical Experimental Research.

31 Aug 2010

Standard dose of UFH optimal for treatment of PCI patients on fondaparinux: Study

A landmark international study, coordinated by McMaster University, has found that lower doses of a blood thinner called unfractionated heparin (UFH) during angioplasty did not reduce bleeding or vascular complications compared to standard dose UFH in patients initially treated with a blood thinner, fondaparinux.

31 Aug 2010

Phase 3 AVERROES trial reveals apixaban effective for atrial fibrillation patients unsuitable for warfarin

The phase 3 AVERROES (Apixaban Versus Acetylsalicylic acid (ASA) to Prevent Strokes) trial, designed to show the superiority of apixaban over aspirin for the prevention of stroke or systemic embolism in high-risk atrial fibrillation patients unsuitable for treatment with a vitamin K antagonist (warfarin), was terminated early following a recommendation from the Data Monitoring Committee.

31 Aug 2010

Genetic profiling to predict treatment benefits of ACE inhibitor therapy for CAD

The advantages of prescribing angiotensin-converting enzyme (ACE) inhibitors for stable coronary artery disease (CAD) may be increased by targeting the therapy to the patients most likely to benefit.Clinical characteristics alone do not allow a reliable identification of these patients, so a research programme was carried out at Erasmus University Medical Centre in Rotterdam to develop a genetic profiling model that predicts the treatment benefits of ACE inhibitors and optimises the recommended therapy.

31 Aug 2010

Using clopidogrel, PPIs increases cardiac damage risk: Study

Patients with coronary artery disease undergoing stent implantation are often prescribed the antiplatelet drug, clopidogrel. This drug prevents blood clots, but is known to have a side-effect that can cause stomach bleeding. Consequently, many users are also prescribed a proton pump inhibitor (PPI). Now, however, a meta-analysis of almost 160,000 patients carried out at the Medical University of Vienna and Wilhelminenhospital, Vienna, has shown that simultaneous use of these drugs can increase the risk of cardiac damage.

31 Aug 2010

Data suggests BIMA improves coronary artery bypass graft efficiency

Recent trial data indicate that coronary artery bypass graft (CABG) surgery remains the most effective intervention for patients with severe coronary artery disease (CAD).

31 Aug 2010

Patients with atherothrombosis are at increased risk of ischemic events: Study

Clinical descriptors can assist clinicians in identifying patients with various stages of atherothrombosis (abnormal fatty deposits in an artery) who are at high-risk of future cardiovascular events, according to a study that will appear in the September 22 issue of JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology meeting in Stockholm.

30 Aug 2010

Low doses of n-3 fatty acids do not reduce overall rate of major cardiovascular events

Results from the Alpha Omega Trial, a multicentre, placebo-controlled trial in men and women following myocardial infarction (MI), suggest that low doses of n-3 fatty acids given in the form of enriched margarines do not reduce the overall rate of major cardiovascular events.

30 Aug 2010

Myocardial Infarction News and Research

Bone marrow-derived mononuclear cell therapy benefits patients after severe heart attack

World Congress on Arthrosis to take place in Belgium from September 23 to 26, 2010

Emergency physicians to present research studies at Research Forum 2010

Amorcyte receives patent for chemotactic hematopoietic stem cell product

NewCardio publishes Cardio3KG clinical study for acute cardiac diagnosis

Researchers to study protein fragments released into bloodstream after heart attack

Data from ESC confirms reduction in adverse events with CYPHER Stent

Iroko Cardio International Sàrl announces data on HDB dosing of tirofiban, abciximab in interventional cardiology

InfraReDx receives 510(k) clearance to market LipiScan IVUS Coronary Imaging System

Lack of preparation for winter sports, high altitudes and low temperatures trigger acute myocardial infarction

ESC releases new Clinical Practice Guidelines covering Myocardial Revascularisation

High levels of OPG hormone associated with adverse outcome after myocardial infarction

Incidence of acute myocardial infarction increases among young Italian women: Study

Standard dose of UFH optimal for treatment of PCI patients on fondaparinux: Study

Phase 3 AVERROES trial reveals apixaban effective for atrial fibrillation patients unsuitable for warfarin

Genetic profiling to predict treatment benefits of ACE inhibitor therapy for CAD

Using clopidogrel, PPIs increases cardiac damage risk: Study

Data suggests BIMA improves coronary artery bypass graft efficiency

Patients with atherothrombosis are at increased risk of ischemic events: Study

Low doses of n-3 fatty acids do not reduce overall rate of major cardiovascular events

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News